Hengxu Wei

VP, CMC & Regulatory Affairs at Cullgen


Dr. Hengxu Wei has over 20 years of working experience in NMC pharmaceutical companies. Hengxu joined Cullgen from Roche where he was previously Head of the CMC team at the Roche Innovation Center Shanghai for two years. Prior to Roche, Hengxu worked at Johnson & Johnson at their R&D Shanghai center as their Director of Clinical Supply Chain API. Before J&J, Hengxu worked at GSK for near 20 years, starting first as a synthetic chemist in the USA in 2000, before moving to GSK’s R&D facility in Shanghai in 2008. At both locations, he served in several roles with increasing responsibilities including leading GSK’s CMC R&D efforts for early NCEs as well as a director to build an analytical and process development team in GSK R&D China. Hengxu helped to establish the GSK Regulatory CMC team in China in 2014 and since then has led this team to provide CMC strategies and technical support for IND/NDA for new product development, registration and life cycle management for small molecule and biological products in China. His work and contribution throughout his career has focused primarily in the area of CMC R&D and clinical materials supplies to ensure the delivery of cGMP and non-GMP batch materials for nonclinical and clinical studies. He has gained extensive experience through leading teams and working on many projects at different stages of development spanning from pre-clinical phase to commercial launch.

Hengxu obtained his Masters degree from the Shanghai Institute of Organic Chemistry, China Academia, and his Ph.D degree in organic synthesis from the University of Lausanne, Switzerland. He spent two years as a postdoctoral researcher focusing on the total synthesis of natural products in KC Nicholas group at the Scripps Research Institute in San Diego, California, USA.



  • VP, CMC & Regulatory Affairs

    Current role

View in org chart